136 related articles for article (PubMed ID: 16245927)
1. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
3. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
5. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.
Bardelli A; Basile ML; Audero E; Giordano S; Wennström S; Ménard S; Comoglio PM; Ponzetto C
Oncogene; 1999 Feb; 18(5):1139-46. PubMed ID: 10022119
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Yamamoto N; Mammadova G; Song RX; Fukami Y; Sato K
J Cell Sci; 2006 Nov; 119(Pt 22):4623-33. PubMed ID: 17062641
[TBL] [Abstract][Full Text] [Related]
7. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
9. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
[TBL] [Abstract][Full Text] [Related]
10. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.
Morello S; Olivero M; Aimetti M; Bernardi M; Berrone S; Di Renzo MF; Giordano S
J Cell Physiol; 2001 Dec; 189(3):285-90. PubMed ID: 11748586
[TBL] [Abstract][Full Text] [Related]
11. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
12. A novel germ line juxtamembrane Met mutation in human gastric cancer.
Lee JH; Han SU; Cho H; Jennings B; Gerrard B; Dean M; Schmidt L; Zbar B; Vande Woude GF
Oncogene; 2000 Oct; 19(43):4947-53. PubMed ID: 11042681
[TBL] [Abstract][Full Text] [Related]
13. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
14. Silencing the MET oncogene leads to regression of experimental tumors and metastases.
Corso S; Migliore C; Ghiso E; De Rosa G; Comoglio PM; Giordano S
Oncogene; 2008 Jan; 27(5):684-93. PubMed ID: 17684486
[TBL] [Abstract][Full Text] [Related]
15. Oligomerization-induced differential dephosphorylation of c-Met receptor tyrosine kinase.
Sheth PR; Watowich SJ
Biochemistry; 2005 Aug; 44(33):10984-93. PubMed ID: 16101282
[TBL] [Abstract][Full Text] [Related]
16. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
Miyata Y; Kanetake H; Kanda S
Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575
[TBL] [Abstract][Full Text] [Related]
17. K252a inhibits the oncogenic properties of Met, the HGF receptor.
Morotti A; Mila S; Accornero P; Tagliabue E; Ponzetto C
Oncogene; 2002 Jul; 21(32):4885-93. PubMed ID: 12118367
[TBL] [Abstract][Full Text] [Related]
18. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
Rudrabhatla P; Rajasekharan R
Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
[TBL] [Abstract][Full Text] [Related]
20. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
